Figure S5 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

Kohei Takano; Mayuko Yukiura; Kazuki Takahashi; Michiko Kitamura; Hiroko Okuno; Yoshinobu Shiose; Kokichi Honda; Kazunori Oyama; Makiko Yamada; Wataru Obuchi; Kazuyoshi Kumagai; Ken Sakurai; Riki Goto; Akiko Zembutsu; Takashi Kagari; Yuki Abe; Toshinori Agatsuma

doi:10.1158/1535-7163.30985682

Figure S5 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

2026 Open access

Read full text

Authors: Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, Kazuyoshi Kumagai, Ken Sakurai

+5 more

Riki Goto, Akiko Zembutsu, Takashi Kagari, Yuki Abe, Toshinori Agatsuma

DOI: 10.1158/1535-7163.30985682

Cited by: 0

Abstract

Correlation analysis of the efficacy of DS-3939a and TA-MUC1 expression in evaluated PDX models.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Neuroblastoma Research and Treatments Glycosylation and Glycoproteins Research

Publication details

Publication date: 2 January 2026